NCT05811169Active, not recruiting
Quest for Tumour Evolution of Non-small Cell Lung Cancer
Quest for Tumour Evolution of Non-small Cell Lung Cancer in Chinese (Unicorn-Quest)
Source: ClinicalTrials.gov · Last updated 13 Apr 2023
Brief summary (registry, in English)
To study and comprehend the evolutionary and genomic landscape between primary and metastatic sites and the dynamics of intratumour and intertumour heterogeneity over time with reference to the treatment modalities for each Chinese patient with non-small cell lung cancer.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 60 (estimated)
- First submitted
- 26 Feb 2023
- Start date
- 15 Feb 2023
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- The University of Hong Kong
- Diseases
- Lung cancer
- NCT number
- NCT05811169
What you commit to
- Study type: Observational
- Planned participants: 60
- From 15 Feb 2023 to the primary completion date, 31 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Any other\* malignancy diagnosed or relapsed at any time, which is currently being treated (including by hormonal therapy).
- Any other\* current malignancy or malignancy diagnosed or relapsed within the past 3 years\*\*.
- \*Exceptions are: non-melanomatous skin cancer, stage 0 melanoma in situ, and in situ cervical cancer
- \*\*An exception will be made for malignancies diagnosed or relapsed more than 2, but less than 3, years ago only if a pre-operative biopsy of the lung lesion has confirmed a diagnosis of NSCLC.
- Psychological condition that would preclude informed consent
Who the study is looking for
- Written Informed consent
- Patients ≥18 years of age, with histologically confirmed non-squamous non-small cell lung cancer who plan to receive active anti-cancer treatment for their non-small cell lung cancer.
- Sufficient tissues with a minimum of two tumour or nodal regions are available for the study based on pre-operative imaging and post-operative pathological findings.
Age in the registry: 18 years to - · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Clinical Oncology, Queen Mary Hospital Coordinator of this site? Confirm its status | Hong Kong | Hong Kong SAR China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.